Higher rates of COVID-19 but less severe infections reported for patients on dupilumab: A big data analysis of the world health organization vigibase

Basit Öğe Kaydı
dc.contributor.authorMahroum, Naim
dc.contributor.authorDamiani, G.
dc.contributor.authorWatad, A.
dc.contributor.authorAmital, H.
dc.contributor.authorBragazzi N. L.
dc.contributor.authorFarah, R.
dc.contributor.authorWu, J.
dc.contributor.authorKong, J.D.
dc.contributor.authorBridgewood, C.
dc.contributor.authorMcgonagle, D.
dc.contributor.authorKhamisy-Farah, R.
dc.date.accessioned2021-10-15T06:27:23Z
dc.date.available2021-10-15T06:27:23Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractObjective: Dupilumab (Dupixent ®) is a monoclonal antibody that inhibits IL- 4 and IL-13 signaling used for the treatment of allergic diseases. Whilst biologic therapy is traditionally regarded as immunosuppressive and capable to increase the infectious risk, Dupilumab does not display these characteristics and may be even protective in certain cases. We investigated the link between Dupilumab therapy and SARS-CoV-2 infection. Materials and Methods: We carried out a comprehensive data mining and disproportionality analysis of the WHO global pharmacovigilance database. One asymptomatic COVID-19 case, 106 cases of symptomatic COVID-19, and 2 cases of severe COVID-19 pneumonia were found. Results: Dupilumab treated patients were at higher risk of COVID-19 (with an IC0.25of 3.05), even though infections were less severe (IC0.25of -1.71). The risk of developing COVID-19 was significant both among males and females (with an IC0.25of 0.24 and 0.58, respectively). The risk of developing COVID-19 was significant in the agegroup of 45-64 years (with an IC0.25of 0.17). Conclusions: Dupilumab use seems to reduce COVID-19 related severity. Further studies are needed to better understand the immunological mechanisms and clinical implications of these findings. Remarkably, the heterogenous nature of the reports and the database structure did not allow to establish a cause-effect link, but only an epidemiologically decreased risk in the patients subset treated with dupilumab.
dc.identifier.citationMahroum, N., Damiani, G., Watad, A., Amital, H., Bragazzi N. L., Farah, R. ... Khamisy-Farah, R. (2021). Higher rates of COVID-19 but less severe infections reported for patients on dupilumab: A big data analysis of the world health organization vigibase. European Review for Medical and Pharmacological Sciences, 25(18), 5865-5870. https://dx.doi.org/10.26355/eurrev_202109_26808
dc.identifier.doi10.26355/eurrev_202109_26808
dc.identifier.endpage5870
dc.identifier.issn1128-3602
dc.identifier.issue18
dc.identifier.scopusqualityQ2
dc.identifier.startpage5865
dc.identifier.urihttps://dx.doi.org/10.26355/eurrev_202109_26808
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8454
dc.identifier.volume25
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherVerduci Editore s.r.l
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectAsthma
dc.subjectAtopic Dermatitis
dc.subjectBig Data
dc.subjectBiologic Therapy
dc.subjectCOVID-19
dc.subjectData Mining
dc.subjectDupilumab
dc.subjectNasal Polyposis
dc.subjectPharmacovigilance
dc.subjectSARS-CoV-2
dc.titleHigher rates of COVID-19 but less severe infections reported for patients on dupilumab: A big data analysis of the world health organization vigibase
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Mahroum-N-2021.pdf
Boyut:
370.02 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu